Ingenol mebutate inhibits the growth of pancreatic cancer cells in vitro via STING with an efficacy comparable to that of clinically used anticancer agents

[1]  P. Nelemans,et al.  Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis: A Secondary Analysis of a Randomized Clinical Trial. , 2022, JAMA dermatology.

[2]  Xinghuo Wu,et al.  Cytosolic escape of mitochondrial DNA triggers cGAS-STING-NLRP3 axis-dependent nucleus pulposus cell pyroptosis , 2022, Experimental & Molecular Medicine.

[3]  L. Du,et al.  The Function of cGAS-STING Pathway in Treatment of Pancreatic Cancer , 2021, Frontiers in Immunology.

[4]  K. Rajapakshe,et al.  High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege , 2021, Journal for ImmunoTherapy of Cancer.

[5]  D. Tang,et al.  The STING1 network regulates autophagy and cell death , 2021, Signal Transduction and Targeted Therapy.

[6]  Xuelian Xu,et al.  Sequential receptor-mediated mixed-charge nanomedicine to target pancreatic cancer, inducing immunogenic cell death and reshaping the tumor microenvironment. , 2021, International journal of pharmaceutics.

[7]  Zhijun Sun,et al.  Turning cold tumors into hot tumors by improving T-cell infiltration , 2021, Theranostics.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  C. Verbeke,et al.  Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing , 2020, Cancers.

[10]  S. Miyata,et al.  3EZ, 20Ac-ingenol-induced Apoptosis in Chemoresistant Cancers With Cyclin D1 Accumulation , 2020, AntiCancer Research.

[11]  M. O'Hara,et al.  Challenges and Opportunities for Pancreatic Cancer Immunotherapy. , 2020, Cancer cell.

[12]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[13]  M. Gale,et al.  Interleukin-1β Induces mtDNA Release to Activate Innate Immune Signaling via cGAS-STING. , 2019, Molecular cell.

[14]  M. Riese,et al.  STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models , 2019, Journal of Immunotherapy for Cancer.

[15]  R. Reis,et al.  Modified ingenol semi-synthetic derivatives from Euphorbia tirucalli induce cytotoxicity on a large panel of human cancer cell lines , 2019, Investigational New Drugs.

[16]  R. Turkington,et al.  Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes , 2018, World journal of gastroenterology.

[17]  E. Jaffee,et al.  Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. , 2018, JCI insight.

[18]  G. Turcatti,et al.  Targeting STING with covalent small-molecule inhibitors , 2018, Nature.

[19]  K. Schroder,et al.  IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate , 2016, PloS one.

[20]  C. Saslis-Lagoudakis,et al.  Global medicinal uses of Euphorbia L. (Euphorbiaceae). , 2015, Journal of ethnopharmacology.

[21]  R. Dummer,et al.  Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2 , 2015, Molecular Cancer Therapeutics.

[22]  C. V. van Eijck,et al.  Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells , 2014, Journal of cellular and molecular medicine.

[23]  G. Barber,et al.  Cyclic Dinucleotides Trigger ULK1 (ATG1) Phosphorylation of STING to Prevent Sustained Innate Immune Signaling , 2013, Cell.

[24]  P. Baran,et al.  14-Step Synthesis of (+)-Ingenol from (+)-3-Carene , 2013, Science.

[25]  P. Blumberg,et al.  RasGRPs Are Targets of the Anti-Cancer Agent Ingenol-3-Angelate , 2013, PloS one.

[26]  Xiaoping Zhou,et al.  Interferon Induced IFIT Family Genes in Host Antiviral Defense , 2013, International journal of biological sciences.

[27]  M. Diamond,et al.  The broad-spectrum antiviral functions of IFIT and IFITM proteins , 2012, Nature Reviews Immunology.

[28]  S. Ogbourne,et al.  PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: Results of a randomized phase IIa trial , 2010, The Australasian journal of dermatology.

[29]  S. Ogbourne,et al.  PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: Results of a randomized, double‐blind, vehicle‐controlled, multicentre, phase IIa study , 2009, The Australasian journal of dermatology.

[30]  G. Vitale,et al.  Type I Interferons in the Treatment of Pancreatic Cancer: Mechanisms of Action and Role of Related Receptors , 2007, Annals of surgery.

[31]  D. Kavanagh,et al.  Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate1 , 2006, The Journal of Immunology.

[32]  F. Khanim,et al.  PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. , 2005, Blood.

[33]  M. Kornmann,et al.  Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy. , 2005, Anticancer research.

[34]  P. Hersey,et al.  Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. , 2004, Molecular cancer therapeutics.

[35]  P. Blumberg,et al.  Characterization of the interaction of ingenol 3-angelate with protein kinase C. , 2004, Cancer research.

[36]  P. Parsons,et al.  Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. , 2004, Cancer research.

[37]  U. Kikkawa,et al.  Establishment of a binding assay for protein kinase C isozymes using synthetic C1 peptides and development of new medicinal leads with protein kinase C isozyme and C1 domain selectivity. , 2002, Pharmacology & therapeutics.

[38]  Y. Nishizuka,et al.  Taxonomy and function of C1 protein kinase C homology domains , 1997, Protein science : a publication of the Protein Society.